Ionis Pharma IONS

HealthcareMarket cap $8B3 connections

Ionis pioneered antisense oligonucleotide (ASO) therapy - drugs that bind to disease-causing RNA and silence it before harmful proteins are made. Spinraza (spinal muscular atrophy), Waylivra, and Tegsedi came from Ionis. 30+ programs in clinical development span neurological, cardiovascular, and rare diseases.Partners including Biogen, Roche, and AstraZeneca validate its platform.

Explore Ionis Pharma on the interactive map Relationship timeline Find a path to another company

Partners 3

Strategic partnerships, joint products and alliances

PfizerHealthcare · $160BAstraZeneca antisense drug partnership with Ionis
BiogenHealthcare · $35BIonis co-develops neurological drugs with Biogen
Alnylam PharmaHealthcare · $25BCompeting RNA silencing therapeutic companies

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Ionis Pharma's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=IONS" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Ionis Pharma on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.